ESC 365 - Vericiguat in heart failure patients: analyzing safety, tolerability, and quality of life via meta-analysis of randomized controlled trials

ESC Premium Access

Vericiguat in heart failure patients: analyzing safety, tolerability, and quality of life via meta-analysis of randomized controlled trials

Session: Heart failure: drug therapy and multidisciplinary care

Topic: Pharmacotherapy

Speaker: Assistant Professor L. Tanriverdi (Malatya, TR)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Assistant Professor Lokman Hekim Tanriverdi

Inonu University, Malatya (Türkiye)

1 follower

6 more presentations in this session

Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Speaker: Doctor S. Matsumoto (Tokyo, JP)

Systematic review and meta-analysis on the effects of physical activity-based interventions on frailty status and clinical outcomes in adults with long-term cardiac conditions.

Speaker: Ms H. Waterhouse (Leicester, GB)

Assessing the practicality of a novel heart failure therapeutic score (QUAD Score) for drug optimisation in heart failure with a reduced ejection fraction

Speaker: Doctor A. Ganapathy (Basildon, GB)

Short-term effects on sacubitril/valsartan therapy on right ventricle work and mechanics in patients with heart failure and reduced ejection fraction

Speaker: Doctor J. Ottela (Turku, FI)

Cardiovascular mortality with oral potassium-binders in patients with CKD and heart failure

Speaker: Doctor H. Barzkar (Dallas, US)

Access the full session

Heart failure: drug therapy and multidisciplinary care

Speakers: Assistant Professor L. Tanriverdi, Doctor S. Matsumoto, Ms H. Waterhouse, Doctor A. Ganapathy, Doctor J. Ottela...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources